Blood Cancer Talks
Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
Episodes
Mentioned books
Oct 13, 2022 • 48min
Episode 7. Newly Diagnosed Ph-negative ALL
Key papers discussed in the show: 1. Pediatric regimen for older adolescents and young adults with ALL: CALGB 10403 https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and2. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: C19802 https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.276173. Rituximab in B-ALL https://www.nejm.org/doi/full/10.1056/NEJMoa16050854. A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia: SWOG 1318 https://ascopubs.org/doi/abs/10.1200/JCO.21.017665. Blinatumomab for MRD in adults with B-ALL https://ashpublications.org/blood/article/131/14/1522/36655/Blinatumomab-for-minimal-residual-disease-in6. Ph-like ALL https://www.nejm.org/doi/10.1056/NEJMoa1403088
Sep 28, 2022 • 48min
Episode 6. Donor Search for Allogeneic Hematopoietic Stem Cell Transplant
Key papers discussed in the show:1. Landmark paper on HLA-mismatch and survival: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568127/2. HLA-DP and Risk of GVHD: https://www.nejm.org/doi/full/10.1056/NEJMoa15001403. Outcomes of Allogeneic Transplant with HLA-Mismatched Unrelated Donor: https://ascopubs.org/doi/10.1200/JCO.20.035024. Review/perspective on fundamentals of unrelated donors and cord blood units: https://ashpublications.org/blood/article/120/2/259/30405/A-perspective-on-the-selection-of-unrelated-donors5. HLA-DQ heterodimers and HCT: https://ashpublications.org/blood/article-abstract/139/20/3009/484363/HLA-DQ-heterodimers-in-hematopoietic-cell6. PT-Cy as GVHD prophylaxis after HCT: https://pubmed.ncbi.nlm.nih.gov/20124511/7. Comparative outcome of MUD vs Haplo-HCT from Registry data: https://ashpublications.org/blood/article/138/3/273/475738/HLA-haploidentical-vs-matched-unrelated-donor
Sep 14, 2022 • 41min
Episode 5. Mentorship and Career Development
In this episode, we do a thought provoking discussion with Dr. Marty Tallman on mentorship and career development in academic hematology and medical oncology. A must listen for all trainees and early career clinical investigators. Sage wisdom from a legend in the field!
Aug 24, 2022 • 1h 3min
Episode 4. Measurable Residual Disease in AML
2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006
5 snips
Aug 10, 2022 • 46min
Episode 3. Management of Waldenström Macroglobulinemia
https://ascopubs.org/doi/abs/10.1200/JCO.22.00495
Jul 27, 2022 • 32min
Episode 2. CAR T-Cell Therapy in Multiple Myeloma
In this episode, we discuss with Dr. Surbhi Sidana the latest advances, practical aspects of patient management, and future directions of cellular therapies in multiple myeloma.
Jul 15, 2022 • 51min
Episode 1. Implications of Clonal Hematopoiesis
In this episode, we bring two experts in clonal hematopoiesis, Dr. Sid Jaiswal from Stanford University and Dr. Alex Bick from Vanderbilt University to dissect the biology, potential clinical implications, and future of clonal hematopoiesis.
Jul 8, 2022 • 2min
Introduction to BloodCancerTalks
BloodCancerTalks is a new podcast focusing exclusively on hematologic malignancies. We will bring a wide range of experts to dig deep into specific topics and critically appraise the literature.
Raj Chakraborty is a hematologist/oncologist and an Assistant Professor of Medicine at Columbia University. Ash Kishtagari is a hematologist/oncologist and an Assistant Professor of Medicine at Vanderbilt University.
